Johnson & Johnson to Participate in the Leerink Partners 6th Annual Global Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- AI stocks lift Wall St as oil falls, Treasury yields decline
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
- Novo Nordisk shares drop as investor event disappoints
Johnson & Johnson (JNJ) PT Lowered to $141 at UBS Following 4Q Report
January 25, 2017 8:12 AM ESTUBS lowered its price target on Johnson & Johnson (NYSE: JNJ) to $141.00 (from $142.00) while maintaining a Buy rating following the company's 4Q earnings report.
Analyst Matt Miksic commented, "After making appropriate adjustments for year-over-year shipping day differences, JNJ's Q4 sales were up... More
